[Treatment strategy of high malignancy non-Hodgkin lymphomas].
While radiotherapy is not justified as a single-modality approach in high-grade non-Hodgkin's lymphoma, standard therapy consists of chemotherapy with the CHOP regimen, which induces complete remissions in ca. 2/3 of the patients, with or without additional radiotherapy. Since the majority of these remissions do not last, dose escalations up to myeloablative ranges using hematopoietic stem cell support are being evaluated especially in young patients with bad risk factors. The trials of the German Non-Hodgkin's Lymphoma Consensus Trial group determine the value of a consolidating high-dose chemotherapy in young patients with high-risk profile, while dose intensifications of the CHOP regimen by two-week regimens and/or the incorporation of etoposide are being evaluated in all other treatment groups.
Pfreundschuh
M
M
Innere Medizin I, Universitätskliniken, Homburg/Saar.
Trümper
L
L
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D009367:Neoplasm Staging; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D016896:Treatment Outcome; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
Behandlungsstrategien bei hochmalignen Non-Hodgkin-Lymphomen.